REG - Tissue Regenix Group - Grant of share options

Tissue RegenixAnnouncement

04/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nRSD7055Pa&default-theme=true

RNS Number : 7055P  Tissue Regenix Group PLC  04 July 2025

 Tissue Regenix Group plc

('Tissue Regenix' or 'the Group')

 

Grant of share options

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that on 1 July 2025 Daniel Lee, Chief Executive Officer, was  granted an
award of restricted share units ("RSU"), and Kirsten Lund, EMEA Business
Director, was granted a Conditional Share Award (CSA), all with respect to
ordinary shares in the capital of the Company ("Ordinary Shares") under the
existing annual Tissue Regenix Share Incentive Plan following the publication
of the 2025 annual report.

 

Daniel Lee has been awarded 428,711 RSU, and Kirsten Lund has been awarded
119,380 CSA, where each RSU/CSA that vests shall represent the right to
receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p
per Ordinary Share. The RSU/CSA are subject to continued service over a period
of three years and satisfaction of customary performance conditions relating
to growth in total shareholder return, annual revenue targets, annual
profitability targets and personal performance targets (the "Options").

 

Following the grant of these Options, Daniel Lee hold options over a total of
1,078,135 RSU representing 1.53% of the current issued share capital
respectively. Kirsten Lund holds options over a total of 305,176 CSA
representing 0.43% of the current issued share capital.

 

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                via Walbrook PR

 David Cocke, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                             Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
'MAR' EU no.596/2014. Upon the publication of this announcement via the
Regulatory Information Service 'RIS', this inside information is now
considered to be in the public domain.

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated ("PCA")
with them.

    1     Details of the person discharging managerial responsibilities / person closely

        associated

 a)       Name                                                         Daniel Lee

 2        Reason for the notification

 a)       Position/status                                              CEO

 b)       Initial notification /Amendment                              Initial notification

 3        Details of the issuer, emission allowance market participant, auction

        platform, auctioneer or auction monitor

 a)       Name                                                         Tissue Regenix Group plc

 b)       LEI                                                           213800PNOD5UHQUFJI36

 4        Details of the transaction(s): section to be repeated for (i) each type of

        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
          place where transactions have been conducted
 a)       Description of the financial instrument, type of instrument  Restricted share units ("RSUs") with respect to Ordinary Shares in the capital

                                                            of the Company of 0.1p

 b)       Identification code                                          GB00B5SGVL29

 c)       Nature of the transaction                                    Issue of options

 d)       Price(s) and volume(s)                                       Volume(s):

                                                                       428,711 RSUs

                                                                       Price: 0.1 pence per RSU
 d)       Aggregated information

          - Aggregated volume                                          N/A

          - Price
 e)       Date of the transactions                                     1 July 2025

 f)       Place of the transaction                                     Outside of a trading venue

 

 

    1     Details of the person discharging managerial responsibilities / person closely

        associated

 a)       Name                                                         Kirsten Lund

 2        Reason for the notification

 a)       Position/status                                              EMEA Business Director

 b)       Initial notification /Amendment                              Initial notification

 3        Details of the issuer, emission allowance market participant, auction

        platform, auctioneer or auction monitor

 a)       Name                                                         Tissue Regenix Group plc

 b)       LEI                                                           213800PNOD5UHQUFJI36

 4        Details of the transaction(s): section to be repeated for (i) each type of

        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
          place where transactions have been conducted
 a)       Description of the financial instrument, type of instrument  Conditional Share awards with respect to Ordinary Shares in the capital of the

                                                            Company of 0.1p

 b)       Identification code                                          GB00B5SGVL29

 c)       Nature of the transaction                                    Issue of options

 d)       Price(s) and volume(s)                                       Volume(s):

                                                                       119,380 CSAs

                                                                       Price: 0.1 pence per SCA
 d)       Aggregated information

          - Aggregated volume                                          N/A

          - Price
 e)       Date of the transactions                                     1 July 2025

 f)       Place of the transaction                                     Outside of a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPKNBDBBKBCOK